Skip to main content

Advertisement

Table 5 Comparison of responders versus non-responders with regard to cancer type, gender, prior treatment history, stage at diagnosis and baseline 25(OH)D levels (N = 799)

From: Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology

Characteristic Responders (n = 441) Non-responders (n = 358) Chi-square p-value
Cancer Site    
   Breast 103 (56.6) 79 (43.4)  
   Lung 83 (69.2) 37 (30.8)  
   Pancreas 28 (46.7) 32 (53.3) < 0.001
   Colorectal 42 (46.7) 48 (53.3)  
   Prostate 42 (70) 18 (30)  
   Others 143 (49.8) 144 (50.2)  
Gender    
   Males 153 (57.5) 113 (42.5) 0.35
   Females 288 (54.0) 245 (46.0)  
Treatment History    
   Newly Diagnosed 233 (56.8) 177 (43.2) 0.34
   Previously Treated 208 (53.5) 181 (46.5)  
Stage at Diagnosis    
   Stage 0 3 (37.5) 5 (62.5)  
   Stage 1 56 (52.8) 50 (47.2)  
   Stage 2 91 (55.5) 73 (44.5) 0.82
   Stage 3 117 (56.3) 91 (43.8)  
   Stage 4 139 (57) 105 (43)  
   Indeterminate 35 (55.2) 34 (44.8)  
Baseline serum 25(OH)D    
   < 12 ng/ml 55 (35.3) 101 (64.7)  
   12-20 ng/ml 145 (55.1) 118 (44.9) < 0.001
   20-32 ng/ml 241 (63.4) 139 (36.6)  
  1. Numbers in parenthesis are row percentages